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Abstract The GAFa domain of the cGMP-binding, cGMP-
speci¢c phosphodiesterase (PDE5A) was modeled on the crystal
structure of PDE2A GAF domain and residues involved in
cGMP binding identi¢ed. Tandem GAFa and GAFb domains
of PDE5A, expressed in Escherichia coli, bound cGMP (Kd 27
nM). Mutation of aspartate-299 in GAFa, suggested earlier to
be critical for cGMP binding, did not abrogate cGMP binding,
but mutation of F205, which formed a stacking interaction with
the guanine ring of cGMP, led to complete loss of cGMP bind-
ing. Therefore, the GAFa domain of PDE5A adopts a structure
similar to the GAFb domain of PDE2A, and provides the sole
site for cGMP binding in PDE5A.
+ 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The cGMP-binding, cGMP-speci¢c phosphodiesterase
PDE5A1, identi¢ed as the target of the drug sildena¢l [1], is
a multi-domain protein that appears to be regulated intri-
cately by phosphorylation as well as binding of cGMP to
allosteric cGMP-binding sites at the N-terminus of the protein
[2,3]. Based on sequence homology in the full-length PDE5A
protein, it appears that there are two cGMP-binding do-
mains arranged in tandem that follow an N-terminal domain
harboring a site for phosphorylation, and preceding the
C-terminal catalytic domain of the enzyme [4]. PDE5A is a
dimer, and regions mediating the dimerization have been sug-
gested to be present in the allosteric cGMP-binding domain
[5^7].
The cGMP-binding sites are representative of ‘GAF’ do-
mains, so named because of the presence of similar motifs
in the genomes of a number of organisms, and in a variety
of proteins including other members of the phosphodiesterase
family [8^10]. Biochemical studies performed with the full-
length recombinant bovine PDE5A enzyme suggested that
there were two cGMP binding sites present in the enzyme,
based on kinetic analysis of binding [11]. Site-directed muta-
genesis analysis in the full-length enzyme indicated the impor-
tance of an aspartate residue at position 289 in the bovine
PDE5A GAFa sequence that was critical for binding
cGMP, and perhaps providing discrimination between
cAMP and cGMP at this site [12,13]. Abolishment of
cGMP binding to the GAF domain did not alter the catalytic
activity of the enzyme, but regulated the ability of PDE5A to
be phosphorylated by protein kinase G, suggesting a regula-
tory role for this domain in the feed-back control of cGMP
levels in the cell [2].
A putative GAF domain protein from yeast, YKG9, was
expressed and crystallized to serve as a structural model for
understanding GAF domains in other proteins, including the
phosphodiesterases [8,14]. The expressed protein did not bind
cGMP, but the crystal structure was used to model the GAFa
domain of bovine PDE5A, which, when expressed as a fusion
protein with glutathione S-transferase, bound cGMP with a
dissociation constant of 650 nM [9]. More recent studies were
directed to expressing the GAFa domain of human PDE5A as
a GST-fusion protein, as well as a protein that comprised the
entire N-terminus of PDE5A and the two tandem GAFa and
GAFb domains. The proteins bound cGMP, but the a⁄nity
of the longer protein comprising the N-terminus and the
GAFa and GAFb domains was markedly lower, with a dis-
sociation constant of 1.9 WM, suggesting the presence of high
and low a⁄nity binding sites in the protein, as was seen in the
full-length enzyme [15]. Based on the homology model of the
bovine GAFa domain and YKG9, residues comprising
N[KR]Xð514ÞFXð3ÞDE, the ‘NKFDE’ motif suggested to be
involved in interacting with cGMP were identi¢ed [5,9].
The cGMP-stimulated phosphodiesterase, PDE2A, contains
two tandem GAF domains, and binding of cGMP is a pre-
requisite for hydrolysis of cAMP by this enzyme. Recently, a
crystal structure of the GAF domains of PDE2A was reported
and revealed a dimeric protein with cGMP bound to the
GAFb domain, while the GAFa domain provided critical in-
teractions for the dimerization of the protein. Binding analysis
revealed a very high-a⁄nity site for cGMP with a dissociation
constant of 26 nM [5]. PDE5A GAFa has the highest simi-
larity to the GAFb domain of PDE2A, suggesting that this
domain in PDE5A could also bind cGMP with a high a⁄nity.
We have therefore used the PDE2A structure as a model for
re-evaluating the GAF domains of PDE5A. By expression
and mutational analysis of the GAFa and GAFb domains
of PDE5A we show here that a single cGMP binding site is
present in the GAFa site of PDE5A, and also identify a phe-
nylalanine residue that is critical for providing an interaction
with cGMP.
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2. Materials and methods
2.1. Modeling of the GAFa domain of PDE5A
A three-dimensional model of the GAFa of human PDE5A was
generated on the basis of the crystal structure of the GAFb domain
of mouse PDE2A. The suite of programs encoded in COMPOSER
[16] and incorporated in SYBYL (Tripos, St. Louis) was used to
generate the 3-D model of the GAFa of human PDE5A. The struc-
tures of the conserved regions of the GAFb domain of mouse PDE2A
were extrapolated to the equivalent regions of GAFa of human
PDE5A. The variable regions were modeled by identifying a suitable
segment from a known structure in the data bank. A template-match-
ing approach [17] to rank the candidate loops was also used. The best-
ranking loop with no short-contacts with the rest of the protein was
¢tted using the ring-closure procedure of F. Eisenmenger (unpub-
lished). Sidechains were modeled either by extrapolating from the
equivalent positions in the basis structure where appropriate, or by
using rules derived from the analysis of known protein structures [18].
The model thus generated was subjected to energy minimization to get
a re¢ned model for the GAFa domain in SYBYL using the AMBER
force-¢eld [19].
The known crystal structure of the GAFb of mouse PDE2A bound
to cGMP (PDB code 1MCO) [5] was used to generate a model of the
cGMP-bound complex by ¢rst extracting the residues from GAFb of
the 1MCO implicated to interact with atoms in cGMP either directly
or through water molecules, and then superposing them with equiv-
alent residues in the human PDE5A GAFa domain.
2.2. Generation of the GST^GAF: wild type clone
The cloned full-length human PDE5A cDNA was used as a tem-
plate for polymerase chain reaction (PCR) using speci¢c primers (se-
quences available on request) to amplify the GAF domain comprising
residues M134^N583. The fragment was cloned initially into pBlue-
script II KS(+) vector (Stratagene), sequenced, and then subcloned
into pGEX-5X-1 (Pharmacia) to obtain plasmid pGEX-PDE5A
(M134^N583). This would allow the expression of a protein with an
N-terminal fusion to glutathione S-transferase (Fig. 2A).
2.3. Generation of D299A and F205 mutations
An overlap PCR-based approach was used to introduce a single
amino acid mutation in the GAFa domain (D299 to Ala). Details
of primer sequences and PCR conditions are available on request.
The PDE5A (M134^N583)F205A and PDE5A (M134^N583)F205Q muta-
tions were generated using the DpnI method of mutagenesis [20].
The pGEX-PDE5A (M134^N583) plasmid was used as a template to
carry out the mutagenic PCR reaction using overlapping forward and
reverse primers harboring the mutation. The PCR product obtained
was digested with DpnI taken for transformation, and colonies ob-
tained screened for the presence of the mutation by sequencing.
2.4. Expression and puri¢cation of the GST fusion proteins
The plasmid expressing the wild type or mutant GAF domains was
used to transform BL21 (DE3) C43 strain of Escherichia coli. Cells
harboring the plasmid were induced at an A600 of 0.6 with 800 WM
isopropyl L-thiogalactopyranoside (IPTG) for 8^12 h at 30‡C. The
cells were collected by centrifugation, resuspended in sonication bu¡er
(50 mM Tris^HCl, pH 7.4, 1 mM dithiothreitol (DTT), 2 mM EDTA,
100 mM NaCl, 1 Wg/ml benzamidine, 1 Wg/ml soyabean trypsin inhib-
itor and 2 mM phenymethylsulfonyl £uoride) and lysed by sonication,
after which Triton X-100 was added to a ¢nal concentration of 0.1%.
Soluble protein was puri¢ed by application of the lysate obtained
after centrifugation to a column of glutathione Sepharose 6B beads
(Pharmacia). The protein bound to beads was resolved on a 10%
SDS^PAGE and the puri¢ed protein visualized by Coomassie blue
staining (Fig. 2B). The GST^GAF domain protein is predicted to
have a molecular weight of 76 kDa.
2.5. cGMP saturation binding assay
Saturation cGMP binding studies were carried out in a 100 Wl re-
action containing 10 mM sodium phosphate bu¡er, pH 7.4, 1 mM
EDTA and 2.5 mM DTT, in the presence of increasing concentrations
of [3H]cGMP (NEN, USA; 5U1037 to 8U1039 M) and 100 nM of
the puri¢ed protein bound to beads, at 37‡C for 1 h. The binding
reaction was then ¢ltered through GF/C ¢lters (Whatman) and
washed with 10 ml of ice-cold bu¡er (10 mM potassium phosphate,
pH 6.8; 1 mM EDTA). The ¢lters were then dried and radioactivity
measured by liquid scintillation counting in scintillation cocktail (1:1,
2-methoxy ethanol: toluene, 5 g/l PPO). The binding data were then
analyzed using GraphPad Prism (San Diego, CA, USA).
2.6. cGMP dissociation
For cGMP dissociation analysis, cGMP binding was carried out in
binding bu¡er containing 1 WM [3H]cGMP along with the fusion
protein. Binding was carried out for 2 h at 37‡C to establish equilib-
rium, transferred to 4‡C and an aliquot was withdrawn for ¢ltration to
determine the initial bound radioactivity (B0). To initiate dissociation
of [3H]cGMP, unlabeled cGMP to a ¢nal concentration of 100 WM
was added and aliquots withdrawn for ¢ltration at di¡erent time
points (Bt). cGMP dissociation rate was calculated by plotting
ln(Bt/B0) versus time. The slope of the line determined the koff .
3. Results and discussion
Recently, the crystal structure of the tandem GAFa and
GAFb domains of mouse PDE2A indicated that the GAFb
domain of PDE2A alone bound cGMP, while the GAFa do-
main was involved in dimerization [5]. The GAFa domain of
PDE5A shows the highest degree of similarity to the GAFb
domain of PDE2A, and therefore, by analogy, could be the
site for cGMP binding. We therefore modeled the GAFa do-
main of PDE5A using the crystal structure of the GAFb do-
main of PDE2A as a template. An alignment of the two
sequences, based on the structural properties of the residues
of the GAFb domain, is shown in Fig. 1A, and demonstrated
48% identity between the two domains. A model of the com-
plex of the GAFa domain of PDE5A and cGMP was also
generated based on the crystal structure (Fig. 1B).
This structure-based alignment showed the conserved na-
ture of substitutions of residues in secondary structure regions
of PDE5A GAFa, and except for the L1^L2 loop, all the other
loops have comparable sequence length to their equivalent
loops in the GAFb domain of PDE2A. Moreover, all residues
implicated in cGMP binding to the GAFb domain of PDE2A
are conserved or conservatively substituted in the GAFa do-
main of human PDE5A (Fig. 1B). These include D206 (D439
in PDE2A), which is engaged in both back-bone and side-
chain interactions with the guanine base. Interestingly, the
adjacent residue F205 (F438 in PDE2A) is positioned in
such a way that a stacking interaction could occur with the
ring of the phenylalanine and the guanine base, since any
group in the sidechain of F205 (other than the CB atom) is
within 4.5 AV distance from the base ring of cGMP. These
phenylalanine and aspartate residues are replaced by histidine
and methionine in the GAFb domain of PDE5A and isoleu-
cine and glycine in the GAFa domain of PDE2A, and these
could be substitutions which compromise cGMP binding to
these domains.
To con¢rm the predictions of the model, we cloned the
GAF domain of PDE5A based on sequence alignment of
this domain with other proteins [5] containing GAF domains
and expressed the protein as a fusion with GST to aid in its
puri¢cation (Fig. 2A). This is a similar approach as taken
earlier, but the protein used in our studies extends further
to the N-terminus than the earlier construct of the GAFa
domain [15], and does not contain the N-terminus of the
full-length PDE5A that harbors a site for phosphorylation
(Fig. 2A). As was reported earlier [15], the presence of the
N-terminus in the GAF^GST fusion protein did not alter the
binding a⁄nities to the GAF domain, and we therefore chose
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to omit this region from our construct. Equilibrium binding
analysis was performed on the puri¢ed fusion protein and the
data obtained indicated a single site for cGMP binding with a
dissociation constant of 27 nM (Fig. 3A). The a⁄nity that we
report here is very similar to that observed for cGMP binding
to the GAF domain of PDE2A (26 nM) [5], and is higher than
that reported for the earlier GST^GAF domain construct.
Dissociation of cGMP from the GST^GAF domain protein
revealed a single o¡-rate for dissociation of cGMP with a koff
of 0.34W 0.008 h31 (Fig. 3B). These results contrast with those
reported earlier that suggested the presence of two binding
sites in the GAF domain of PDE5A, with the apparently
high-a⁄nity site showing a Kd of 330 nM [15].
The speci¢city of binding of cGMP and cAMP was studied
Fig. 1. Model of the GAFa domain of PDE5A. A: Alignment of the GAFa domain of human PDE5A with the GAFb domain of mouse
PDE2A. Key to the JOY notation: solvent inaccessible; UPPER CASE (O); solvent accessible, lower case (o); positive P, italic (o) ; cis peptide,
breve (o‹); hydrogen bond to other sidechain, tilde (o«); hydrogen bond to main chain amide, bold (o) ; hydrogen bond to main chain carbonyl,
underline (o); disulphide bond, cedilla (c[). B: A model of the PDE5A GAFa^cGMP complex is shown with the cGMP-binding site, and resi-
dues implicated in cGMP binding are highlighted. The ¢gure was generated using SETOR [23].
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and data obtained from inhibition analysis indicated a nearly
1000-fold reduction in a⁄nity for cAMP (Fig. 3C). It is in-
teresting to note that there was only a 10-fold lowering of
a⁄nity of cAMP binding to the PDE2A GAFb domain [5],
indicating that certain structural features in the PDE5A GAF
domains must contribute to the higher speci¢city that is seen
for cGMP over cAMP.
A highly conserved ‘N[KR]Xð514ÞFXð3ÞDE’ motif is present
in nearly all PDE GAF domains, and was suggested to be
critical for cGMP binding, based on mutational analysis of
some of these residues in the GAF domain of bovine PDE5A
[12], as well as recent homology modeling of the bovine
PDE5A GAFa domain on the crystal structure of the yeast
GAF domain containing protein, YKG9 [9]. We mutated res-
idue D299 in GAFa to an alanine and monitored the binding
to the GST^GAF domain protein. In our current model, this
residue lies away from the cGMP-binding site and is therefore
predicted not to alter binding of cGMP appreciably. It was
observed that while the D299A mutation led to a marked
reduction in the Bmax (Fig. 4A), the a⁄nity of binding of
cGMP to the mutant protein was only marginally decreased.
This suggested that there may have been some misfolding of
the fusion protein as a consequence of this mutation, but that
the fraction of protein that retained the ability to bind cGMP
did so with an a⁄nity comparable to the wild type protein.
This is in contrast to results reported earlier with the full-
length bovine PDE5A, where mutation of the corresponding
D residue led to a dramatic reduction in the dissociation con-
stant for cGMP [11].
Fig. 2. PDE5A GST^GAF domain proteins. A: A diagrammatic
representation of various constructs generated in this study for anal-
ysis of the GAF domain of PDE5A. All proteins were expressed as
fusion proteins with GST. Also shown is a summary of the binding
data obtained using the various proteins. B. Puri¢cation of the
GST^GAF domain wild type protein. Coommassie stained gel of
protein (1 Wg) puri¢ed from lysates by glutathione a⁄nity chroma-
tography.
Fig. 3. Binding analysis for wild type GST^GAF. A: Protein bound
to beads (100 nM) was incubated in binding bu¡er in the presence
of increasing concentrations of [3H]cGMP at 37‡C for 1 h, and
binding data were analyzed using GraphPad Prism and ¢tted best
to a one-site binding hyperbola equation. Data shown are represen-
tative of ¢ve separate experiments and values are the meanWS.E.M.
Inset shows the Scatchard plot of the binding data obtained. B:
Dissociation of cGMP bound to the GST^GAF protein was mea-
sured as described in the text. Data shown are representative of ex-
periments performed at least twice. C: Various concentrations of ei-
ther unlabeled cGMP or cAMP were used to inhibit the binding of
radiolabeled cGMP to the puri¢ed GST^GAF protein. Data shown
are representative of experiments performed twice and values are
meanWS.E.M. of duplicate determinations.
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In order to validate the structural model in terms of the
implicated similarity between the GAFa domain of PDE5A
and the GAFb domain of PDE2A, we generated two mutants
where F205 in GAFa was changed to either an alanine or a
glutamine residue, in order to dramatically alter the environ-
ment of the cGMP binding pocket. Mutations were generated
in the GST^GAF domain protein and mutant proteins were
puri¢ed and monitored for cGMP binding. As seen in Fig. 4B,
no binding was detected in either of the mutant proteins,
indicating the critical role for the F residue in directly inter-
acting with cGMP, or maintaining the overall conformation
of the GAFa domain to allow cGMP binding. Preliminary
evidence suggests that the F205A or F205Q mutations do
not alter the phosphodiesterase activity when introduced in
the full-length PDE5 (data not shown), but the low levels of
expression of the GST fusion proteins we obtain in this study
preclude a detailed structural analysis of the consequences of
this mutation on the overall structure of the GST^GAF fu-
sion.
The results presented here have indicated that an earlier
model of the bovine PDE5A GAFa domain that was gener-
ated using a yeast GAF domain protein as template may have
incorrectly predicted the positioning of the cGMP in the pro-
tein. This is justi¢ed based on the observation that the earlier
model predicted the importance of the ‘NK(X)nDE’ motif in
binding cGMP, but our data on the mutation of the D resi-
due, as well as observation of the position of this motif in
relation to cGMP in the current model, preclude a critical
requirement for this motif in direct interaction with cGMP,
as was also observed in PDE2A GAFb [5].
Also interesting to note is that the GAF domain construct
that we have generated has a high a⁄nity for cGMP and is in
very close agreement to that observed for the GAF domain of
PDE2A (27 nM for PDE5A GAF vs. 26 nM for PDE2A
GAF [5]). The protein used in the current study begins at
methionine 134 and ends at asparagine 583, with the number-
ing based on the residues in the human PDE5A1 splice variant
[21,22]. In some of our earlier work, a construct was gener-
ated that began at isoleucine 221 and extended to alanine 645
(Fig. 2A). This protein showed no binding to cGMP, even
though it would have contained the NK(X)nDE motifs (resi-
dues 286^300 in GAFa and 515^527 in GAFb), as well as the
entire GAFb domain. However, F205, which we have shown
here to be critical for cGMP binding, would be absent in this
protein and therefore this could have accounted for the loss of
cGMP binding.
In earlier studies using GST^GAF domain proteins, con-
structs began at valine 165 and extended to aspartate 403 for
the GST^GAFa domain construct, and this protein was re-
ported to have an a⁄nity for cGMP of 330 nM [15]. A similar
construct of the GAFa domain of bovine PDE5A was shown
to have an a⁄nity for cGMP of 650 nM [9]. These results
suggest that the presence of the GAFb domain may increase
the a⁄nity of the GAFa domain for cGMP, as is seen in our
constructs, perhaps aiding in the formation of a correctly
juxtaposed dimer, as was observed in the crystal structure of
PDE2A.
In comparison to the GAF domain of PDE2A GAFb, the
GAF domain of PDE5A shows a much higher speci¢city for
cGMP as compared to cAMP [5]. This could perhaps be ex-
plained from the model because of the presence of arginine
174 that is substituted by an isoleucine in PDE2A. The model
predicts that the sidechain of arginine would be positioned in
PDE5A such that there would be a charge repulsion from the
N6 atom of cAMP, thereby reducing the a⁄nity of binding. It
is likely that the isoleucine residue present in PDE2A may
accommodate cAMP more readily, allowing it to bind with
an a⁄nity only 10-fold lower than that of cGMP.
Our results therefore suggest that the GAF domain of
PDE5A is likely to adopt a structure similar to that of
PDE2A, with critical determinants for cGMP binding being
retained in both proteins. Given the high-a⁄nity binding that
we observe with the PDE5A-GAFa domain construct de-
signed here, additional mutational analyses on full-length
PDE5A are warranted. Since the reported a⁄nity of cGMP
binding for the full-length PDE is much lower than we see
here (Kd 1 WM) it appears that the addition of the catalytic
domain, and perhaps the N-terminal domain of PDE5A, al-
ters the conformation of the GAF domain such that it binds
cGMP with a lower a⁄nity. This could be an advantage in the
cell, where an increase in PDE5A activity, as a consequence of
Fig. 4. Binding analysis for mutant GST^GAFD299A, GST^GAFF205A
and GST^GAFF205Q proteins. A: GST^GAFD299A protein bound to
beads (100 nM) was incubated in binding bu¡er in the presence of
increasing concentrations of [3H]cGMP. The binding data were ana-
lyzed using GraphPad Prism and ¢tted best to a one-site binding
hyperbola. Data shown are representative of three separate experi-
ments, and values are the meanWS.E.M. of duplicate deter-
minations. Insets show a Scatchard plot of the binding data ob-
tained, and a Coomassie stained gel of the puri¢ed mutant protein.
B: GST^GAFF205A and GST^GAFF205Q proteins were puri¢ed and
1 WM used for binding analysis in the presence and absence of unla-
beled cGMP, and in the presence of 100 nM [3H]cGMP. Data
shown are representative of assays performed twice and values are
meanWS.E.M. of duplicate determinations. Inset shows the Coo-
massie stained picture of the puri¢ed mutant proteins. Around 3 nM
of cGMP was bound to the wild type protein, used at 100 nM con-
centration under the assay conditions, representing less than 5% sat-
uration.
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cGMP binding to the GAF domain and phosphorylation of
the enzyme, should occur only on large increases in cGMP
levels, and not at the low nM concentrations that are present
under basal conditions in most cells.
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